Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

@article{Masi2009LongTermOO,
  title={Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases},
  author={Gianluca Masi and Fotios Loupakis and Luca Emanuele Pollina and Enrico Vasile and S Cupini and Sergio Ricci and Isa Maura Brunetti and Roberta Ferraldeschi and Giuseppe Naso and Franco Filipponi and Andrea Pietrabissa and Orlando Goletti and Giacomo Giulio Baldi and Lorenzo Fornaro and Michele Andreuccetti and Alfredo Falcone},
  journal={Annals of Surgery},
  year={2009},
  volume={249},
  pages={420-425}
}
OBJECTIVE/BACKGROUND The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection of metastases in initially unresectable metastatic colorectal cancer. [] Key MethodPATIENTS AND METHODS Overall, 196 patients with initially unresectable metastatic colorectal cancer were treated with FOLFOXIRI in 2 phase II and 1 phase III trial. This regimen was associated with an elevated response rate (70.4%) and 37 patients (19%) could undergo a secondary R0 surgery on metastases.
View on Wolters Kluwer
media.news.health.ufl.edu
227 Citations
Highly Influential Citations
5
Background Citations
64
Methods Citations
6
Results Citations
7

227 Citations

FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.

FOLFOX is an effective chemotherapeutic regimen leading to successful hepatic resection and an excellent prognosis for patients with initially CRLM.

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab

To investigate efficacy and safety of cetuximab combined with neo adjuvant chemotherapy regimen in patients with unresectable colorectal liver. This was a prospective trial with rate of Ro liver…

Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome

Highly chemosensitive patients, whose initially unresectable CRL Ms become resectable because of missing CRLMs left in place, have a favorable long-term outcome.

Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

The addition of bevacizumab to FOLFOXIRI produces high rates of pathologic responses and necrosis of CLM without increasing liver toxicity.

Chance of Cure Following Liver Resection for Initially Unresectable Colorectal Metastases: Analysis of Actual 5-Year Survival

Cure can be achieved in about 23 % of patients resected for initially unresectable CRLM downsized by chemotherapy, and Liver resection can be safely performed in selected patients even after multiple courses of chemotherapy.

Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma

Preoperative bevacizumab-based chemotherapy offers a high surgical rescue rate in patients with initially unresectable mCRC.

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

Six months of induction chemotherapy with FOLFOXIRI is associated with a clinically significant improvement in the long-term outcome compared with F OLFIRI with an absolute benefit in survival at 5 years of 7%.

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

  • R. WongD. Cunningham I. Chau
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
Neoadjuvant CAPOX plus bevacizumab resulted in a high response rate for patients with CLMs with poor-risk features not selected for upfront resection and converted 40% of patients to resectability.
...

References

SHOWING 1-10 OF 32 REFERENCES

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

This new strategy of combining effective chemotherapy with surgery apparently altered the natural history of unresectable colorectal cancer metastases.

Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer

The FOLFOXIRI regimens studied have significant antitumor activity and allow a radical surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer not selected for a neoadjuvant approach and also those with extrahepatic disease.

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases

Surgical resection of liver metastases after neoadjuvant treatment with modified FOLFIRI in CRC patients achieved favourable survival times.

Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival

Modern chemotherapy allows 12.5% of patients with unresectable CRLM to be rescued by liver surgery, with a wide use of repeat hepatectomies and extrahepatic resections, and four preoperative risk factors could select the patients most likely to benefit from this strategy.

Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases

Neoadjuvant chemotherapy enables liver resection in some patients with initially unresectable colorectal metastases and long-term survival is similar to that reported for a priori surgical candidates.

Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.

Liver resection may be achieved in some previously unresectable patients with the help of an effective chemotherapy, and the benefit in survival seems comparable to that obtained with primary liver resection.

Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal.

Neoadjuvant chemotherapy enables liver resection in some patients with initially unresectable colorectal metastases and long-term survival is similar to that reported for a priori surgical candidates.

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

  • T. AloiaM. Sebagh R. Adam
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The main hepatic lesion induced by preoperative FU/oxaliplatin chemotherapy in patients with CLM is vascular and not steatosis, and the risk for other postoperative complications is related to the duration of preoperative chemotherapy administration.

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases, and a strong correlation was found between response rates and the resection rate.

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

The present trial investigated the effectiveness of cetuximab in combination with standard F OLFIRI compared with FOLFIRI alone in the first-line treatment of pts with epidermal growth factor receptor (EGFR)-expressing mCRC.